Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia

Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study

(2015) Paulien Ravenstijn et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia

(2015) Joris Berwaerts et al.   JAMA Psychiatry

Making the Leap from Daily Oral Dosing to Long-Acting Injectables: Lessons from the Antipsychotics

(2014) Julius F. Remenar   MOLECULAR PHARMACEUTICS

A Fast Method for Testing Covariates in Population PK/PD Models

(2011) Akash Khandelwal et al.   AAPS Journal

Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

(2011) Martin Bergstrand et al.   AAPS Journal

Population Pharmacokinetics of Intramuscular Paliperidone Palmitate in Patients with Schizophrenia

(2009) Mahesh N. Samtani et al.   CLINICAL PHARMACOKINETICS

Approaches to handling pharmacodynamic baseline responses

(2008) Chantaratsamon Dansirikul et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS